The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa

Journal of Neural Transmission

Volumn 117, Issue 1, 2010, Pages 55-67

  Jackson, Michael John ^a   Andree, Terrance H ^b   Hansard, Matthew ^a   Hoffman, Diane C ^c   Hurtt, Mark R ^c   Kehne, John H ^c   Pitler, Thomas A ^c   Smith, Lance A ^a   Stack, Gary ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c NEUROGEN CORPORATION   (United States)

Author keywords

Aplindore; MPTP; Parkinson's disease; Partial agonist; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APLINDORE; CARBIDOPA; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; LEVODOPA; ROPINIROLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MAXIMUM PERMISSIBLE DOSE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REPEATED DRUG DOSE;

ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DISABILITY EVALUATION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; LEVODOPA; LOCOMOTION; MALE; MPTP POISONING; RECEPTORS, DOPAMINE D2; TIME FACTORS; TREATMENT OUTCOME;

EID: 76949097352     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0323-9     Document Type: Article

References (29)

1. JE Ahlskog MD Muenter 2001 Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 448 458 10.1002/mds.1090 1:STN:280:DC%2BD3MzitVCmtg%3D%3D 11391738 (Pubitemid 36041148)
2. T Akai M Yamaguchi E Mizuta S Kuno 1993 Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys Ann Neurol 33 507 511 10.1002/ana.410330515 1:CAS:528:DyaK3sXlvFGnu7w%3D 8098931
3. T Akai M Ozawa M Yamaguchi E Mizuta S Kuno 1995 Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys J Pharmacol Exp Ther 273 309 314 1:CAS:528:DyaK2MXltVGlurw%3D 7714782
4. Andree TH, Stack G, Rosenzweig-Lipson S, Coupet J (1999) WAY-135452: a potent novel D2/D3 partial agonist for the treatment of schizophrenia. In: 38th annual meeting of the American College of Neuropsychopharmacology
5. F Baronti MM Mouradian KE Conant M Giuffra G Brughitta TN Chase 1992 Partial dopamine agonist therapy of levodopa-induced dyskinesias Neurology 42 1241 1243 1:STN:280:DyaK383ptlGmsg%3D%3D 1351273
6. D Bravi TL Davis MM Mouradian TN Chase 1993 Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980 Mov Disord 8 195 197 10.1002/mds.870080214 1:STN:280:DyaK3s3jtlKquw%3D%3D 8097280
7. T Brucke K Bankiewicz J Harvey-White I Kopin 1988 The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model Eur J Pharmacol 148 445 448 10.1016/0014-2999(88)90125-2 1:CAS:528: DyaL1cXktVSltrs%3D 3260191
8. A Carlsson 1983 Dopamine receptor agonists: intrinsic activity vs. state of receptor J Neural Transm 57 309 315 10.1007/BF01249001 1:CAS:528: DyaL2cXmt1eruw%3D%3D 6418858
9. MH De Vries MB Hesselink AA Winsemius P Jenner L Johnston S Salvage 2004 SLV 308: plasma levels of effective doses in MPTP-treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans Clin Pharmacol Ther 75 70 10.1016/j.clpt.2003.11.265
10. JC Glennon SG Van E Ronken MB Hesselink JH Reinders NM Van Der SK Long RW Feenstra AC McCreary 2006 In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist Synapse 60 599 608 10.1002/syn.20330 1:CAS:528:DC%2BD28XhtFKkt7fI 17001660 (Pubitemid 44658266)
11. JN Heinrich J Brennan MH Lai K Sullivan G Hornby M Popiolek LX Jiang MH Pausch G Stack KL Marquis TH Andree 2006 Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist Eur J Pharmacol 552 36 45 10.1016/j.ejphar.2006.08.063 1:CAS:528:DC%2BD28XhtFKmurvK 17056032 (Pubitemid 44648072)
12. RG Holloway I Shoulson S Fahn K Kieburtz A Lang K Marek M McDermott J Seibyl W Weiner B Musch C Kamp M Welsh A Shinaman R Pahwa L Barclay J Hubble P LeWitt J Miyasaki O Suchowersky M Stacy DS Russell B Ford J Hammerstad D Riley D Standaert F Wooten S Factor J Jankovic F Atassi R Kurlan M Panisset A Rajput R Rodnitzky C Shults G Petsinger C Waters R Pfeiffer K Biglan L Borchert A Montgomery L Sutherland C Weeks M DeAngelis E Sime S Wood C Pantella M Harrigan B Fussell S Dillon B exander-Brown P Rainey M Tennis E Rost-Ruffner D Brown S Evans D Berry J Hall T Shirley J Dobson D Fontaine B Pfeiffer A Brocht S Bennett S Daigneault K Hodgeman C O'Connell T Ross K Richard A Watts 2004 Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch Neurol 61 1044 1053 10.1001/archneur.61.7.1044 15262734 (Pubitemid 38915945)
13. MJ Jackson LA Smith G Al-Barghouthy S Rose P Jenner 2007 Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets Exp Neurol 204 162 170 10.1016/j.expneurol.2006. 10.005 1:CAS:528:DC%2BD2sXisVWnsb0%3D 17113078 (Pubitemid 46330268)
14. P Jenner 2008 Molecular mechanisms of L-DOPA-induced dyskinesia Nat Rev Neurosci 9 665 677 10.1038/nrn2471 1:CAS:528:DC%2BD1cXhtVSjurvP 18714325
15. Jenner P (2008b) Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities. Mov Disord 23(Suppl 3):S585-S598
16. JH Kehne TH Andree JN Heinrich 2008 D2 receptor partial agonists: treatment of CNS disorders of dopamine function Curr Top Med Chem 8 1068 1088 10.2174/156802608785161394 1:CAS:528:DC%2BD1cXps1Ohtbw%3D 18691133
17. T Kenakin 2002 Drug efficacy at G protein-coupled receptors Annu Rev Pharmacol Toxicol 42 349 379 10.1146/annurev.pharmtox.42.091401.113012 1:CAS:528:DC%2BD38XhvFKnsbc%3D 11807176 (Pubitemid 34160530)
18. M Kuoppamaki G Al-Barghouthy MJ Jackson LA Smith N Quinn P Jenner 2007 L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates J Neural Transm 114 1147 1153 10.1007/s00702-007-0727-3 1:CAS:528:DC%2BD2sXpsFajsro%3D 17446998 (Pubitemid 47313171)
19. KW Lange PA Loschmann H Wachtel R Horowski P Jahnig P Jenner CD Marsden 1992 Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment of common marmosets Eur J Pharmacol 212 247 252 10.1016/0014-2999(92)90337-4 1:CAS:528: DyaK38Xhs1Kiu7s%3D 1350996
20. A Lieberman G Gopinathan A Neophytides P Pasternack M Goldstein 1987 Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa Neurology 37 863 865 1:STN:280:DyaL2s3gt1emsw%3D%3D 3574692
21. E Martignoni C Pacchetti B Aufdembrinke L Godi G Albani F Mancini G Nappi 1995 Terguride in stable Parkinson's disease Funct Neurol 10 143 146 1:STN:280:DyaK287itFeisQ%3D%3D 8557216
22. JA Obeso CW Olanow JG Nutt 2000 Levodopa motor complications in Parkinson's disease Trends Neurosci 23 S2 S7 10.1016/S1471-1931(00)00031-8 1:CAS:528:DC%2BD3cXotVGrt7k%3D 11052214
23. C Pacchetti E Martignoni P Bruggi L Godi B Aufdembrinke C Miltenburger B Voet G Nappi 1993 Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo Mov Disord 8 463 465 10.1002/mds.870080408 1:STN:280:DyaK2c%2FkvFylsQ%3D%3D 7901760
24. RK Pearce M Jackson L Smith P Jenner CD Marsden 1995 Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus) Mov Disord 10 731 740 10.1002/mds.870100606 1:STN:280:DyaK28zmtlegug%3D%3D 8749992 (Pubitemid 26039721)
25. O Rascol DJ Brooks AD Korczyn PP De Deyn CE Clarke AE Lang 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 1484 1491 10.1056/NEJM200005183422004 1:CAS:528:DC%2BD3cXjvVeitrc%3D 10816186 (Pubitemid 30318272)
26. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53(Suppl 3):S3-S12
27. S Ruggieri F Stocchi F Baronti F Viselli R Horowski C Lucarelli A Agnoli 1991 Antagonist effect of terguride in Parkinson's disease Clin Neuropharmacol 14 450 456 10.1097/00002826-199110000-00010 1:STN:280:DyaK38%2Fns1Chsg%3D%3D 1683813
28. LA Smith MJ Jackson MJ Hansard E Maratos P Jenner 2003 Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure Mov Disord 18 487 495 10.1002/mds.10394 12722161 (Pubitemid 36656532)
29. RP Stephenson 1956 A modification of receptor theory Br J Pharmacol Chemother 11 379 393 1:CAS:528:DyaG2sXltlGhtw%3D%3D 13383117